Fluarix Tetra

Fluarix Tetra

vaccine, influenza

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig Pharma
Full Prescribing Info
Contents
Inactivated quadrivalent influenza vaccine (split virion)
Description
Each 0.5 ml vaccine dose contains 15 μg haemagglutinin of each of the recommended strains.
Fluarix Tetra is an inactivated influenza vaccine (split virion), containing antigens (propagated in embryonated eggs) equivalent to the following types and subtypes: A/Brisbane/02/2018 (H1N1)pdm09 - like strain (A/Brisbane/02/2018, IVR-190);
A/South Australia/34/2019 (H3N2) - like strain (A/South Australia/34/2019, IVR-197);
B/Washington/02/2019 - like strain (B/Washington/02/2019, wild type);
B/Phuket/3073/2013 - like strain (B/Phuket/3073/2013, wild type).
This vaccine complies with the WHO recommended strains (Southern Hemisphere) for the season 2020.
Fluarix Tetra meets the WHO requirements for biological substances and influenza vaccines and the European Pharmacopoeia requirements for influenza vaccines.
Excipients/Inactive Ingredients: Sodium chloride, disodium phosphate dodecahydrate, potassium dihydrogen phosphate, potassium chloride, magnesium chloride hexahydrate, α-tocopheryl hydrogen succinate, polysorbate 80, octoxinol 10 and water for injections.
Hydrocortisone, gentamicin sulphate, ovalbumin, formaldehyde and sodium deoxycholate are present as residues from the manufacturing process.
Action
Pharmacology: Pharmacodynamics: Mechanism of Action: Fluarix Tetra induces haemagglutination-inhibition (HI) antibodies against the four influenza virus strains contained in the vaccine. While specific levels of HI antibody in response to inactivated influenza virus vaccines have not been correlated with protection from influenza illness the HI antibody titres have been used as a measure of vaccine activity. In some human challenge studies, HI antibody titres of ≥1:40 have been associated with protection from influenza illness in up to 50% of subjects.
Annual revaccination with the current vaccine is recommended because immunity declines during the year after vaccination, and because circulating strains of influenza virus might change from year to year.
Pharmacodynamic Effects: Efficacy in children 6-35 months of age: The efficacy of Fluarix Tetra was evaluated in clinical study D-QIV-004, a randomised, observer-blind, non-influenza vaccine-controlled trial conducted during influenza seasons 2011 to 2014. Healthy subjects aged 6 through 35 months were randomised (1:1) to receive Fluarix Tetra (N = 6,006) or an age appropriate non-influenza control vaccine (N = 6,012). Subjects were administered 1 dose (in case of history of influenza vaccination) or 2 doses, approximately 28 days apart.
Efficacy of Fluarix Tetra was assessed for the prevention of influenza A and/or B disease (moderate to severe and of any severity) due to any seasonal influenza strain, starting 2 weeks post-vaccination until the end of the influenza season (approximately 6 months later). Fluarix Tetra met the predefined criteria for primary and secondary vaccine efficacy objectives (Table 1). (See Table 1.)

Click on icon to see table/diagram/image

Exploratory analyses were conducted on the Total Vaccinated Cohort (TVC) including 12,018 subjects. Fluarix Tetra was efficacious in the prevention of moderate to severe influenza caused by each of the 4 strains (Table 2), even when there was significant antigenic mismatch with 2 of the vaccine strains (A/H3N2 and B/Victoria). (See Table 2.)

Click on icon to see table/diagram/image

Additionally, for RT-PCR confirmed cases of any severity, Fluarix Tetra reduced the risk of visits to the general practitioner by 47% (Relative Risk (RR): 0.53 [95% CI: 0.46; 0.61], i.e., 310 versus 583 visits) and to the emergency room by 79% (RR: 0.21 [95% CI: 0.09; 0.47], i.e., 7 versus 33 visits). The use of antibiotics was reduced by 50% (RR: 0.50 [95% CI: 0.42; 0.60], i.e., 172 versus 341 subjects).
Immunogenicity in children and adults: Immunogenicity of Fluarix Tetra was evaluated in terms of HI Geometric mean antibody titre (GMT) at 28 days after the last dose (children) or Day 21 (adults) and HI seroconversion rate (4-fold rise in reciprocal titre or change from undetectable [< 10] to a reciprocal titre of ≥ 40).
In study D-QIV-004, the evaluation was performed in a sub-cohort of 1,332 children. The results are presented in Table 3.
The effect of a 2-dose priming schedule in D-QIV-004 was evaluated by assessing the immune response after revaccination one year later with 1 dose of Fluarix Tetra in study D-QIV-009. This study demonstrated that 7 days post-vaccination, immune memory in children 6 to 35 months of age had been elicited for all four vaccine strains.
Immunogenic non-inferiority of Fluarix Tetra was assessed versus Fluarix in children (study D-QIV-003) and in adults (study D-QIV-008). Children received 1 or 2 doses and adults received 1 dose of either vaccine. In both studies, Fluarix Tetra elicited an immune response against the three strains in common that was non-inferior to Fluarix and a superior immune response against the additional B strain included in Fluarix Tetra. The results are presented in Table 3. (See Table 3.)

Click on icon to see table/diagram/image

Concomitant administration with pneumococcal vaccines: In clinical study D-QIV-010 involving 356 adults ≥50 years of age at risk for complications of influenza and pneumococcal diseases, subjects received Fluarix Tetra and 23-valent pneumococcal polysaccharide vaccine (PPV23) either concomitantly or separately. For all four Fluarix Tetra vaccine strains and the six pneumococcal serotypes (1, 3, 4, 7F, 14, and 19A) in PPV23 evaluated in the pre-specified primary analysis, the immune response was non-inferior between the two treatment groups. Based on a descriptive analysis for six additional pneumococcal vaccine serotypes (5, 6B, 9V, 18C, 19F, and 23F), the immune response was comparable between groups, with 91.7% to 100% and 90.7% to 100% of subjects attaining seroprotective antibody levels against these serotypes in the separate and concomitant administration group respectively.
Immunological non-inferiority has been demonstrated based on published data for all 3 Fluarix trivalent strains (D-TIV) and all 13-valent pneumococcal conjugate vaccine (PCV13) serotypes in adults 50-59 years of age, as well as for 2 of 3 D-TIV strains and 12 of 13 PCV13 serotypes in adults >65 years of age. A lower immune response to some pneumococcal serotypes was observed when PCV13 was given concomitantly with D-TIV as compared to separate administration, however the clinical relevance of this observation is unknown.
Toxicology: Pre-clinical Safety Data: Non-clinical data reveal no special hazards for humans based on conventional studies of acute toxicity, local tolerance, repeated dose toxicity and reproductive/developmental toxicity.
Indications/Uses
Fluarix Tetra is a quadrivalent vaccine indicated for active immunisation of adults and children from 6 months of age for the prevention of influenza disease caused by influenza virus types A and B contained in the vaccine (see Pharmacology: Pharmacodynamics under Actions).
Dosage/Direction for Use
Fluarix Tetra should be administered as a single 0.5 ml injection.
Children 6 months to less than 9 years of age who have not previously been vaccinated against influenza should receive a second dose of 0.5 ml after an interval of at least 4 weeks.
Children aged <6 months: The safety and efficacy of Fluarix Tetra in children aged less than 6 months have not been established.
Vaccination should be carried out by intramuscular injection preferably into the deltoid muscle or anterolateral thigh (depending on the muscle mass).
Contraindications
Fluarix Tetra should not be administered to subjects with known hypersensitivity after previous administration of Fluarix Tetra or influenza vaccines or to any component of the vaccine.
Special Precautions
It is good clinical practice to precede vaccination by a review of the medical history (especially with regard to previous vaccination and possible occurrence of undesirable events) and a clinical examination.
As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine.
As with other vaccines, vaccination with Fluarix Tetra should be postponed in subjects suffering from an acute severe febrile illness. The presence of a minor infection, such as a cold, should not result in the deferral of vaccination.
It may be expected that in patients receiving immunosuppressive treatment or patients with immunodeficiency, an adequate immune response may not be elicited.
Fluarix Tetra is not effective against all possible strains of influenza virus. Fluarix Tetra is intended to provide protection against those strains of virus from which the vaccine is prepared and to closely related strains.
As with any vaccine, a protective immune response may not be elicited in all vaccinees.
FLUARIX TETRA SHOULD UNDER NO CIRCUMSTANCES BE ADMINISTERED INTRAVASCULARLY.
As with other vaccines administered intramuscularly, Fluarix Tetra should be given with caution to individuals with thrombocytopenia or any coagulation disorder since bleeding may occur following an intramuscular administration to these subjects.
Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection. It is important that procedures are in place to avoid injury from faints.
Use In Pregnancy & Lactation
The safety of Fluarix Tetra when administered to pregnant women has not been evaluated. Animal studies with Fluarix Tetra do not indicate direct or indirect harmful effects with respect to reproductive and developmental toxicity (see Pharmacology: Toxicology: Pre-clinical Safety Data under Actions).
Fluarix Tetra should be used during pregnancy only when clearly needed, and the possible advantages outweigh the potential risks for the foetus.
The safety of Fluarix Tetra when administered to breast-feeding women has not been evaluated. It is unknown whether Fluarix Tetra is excreted in human breast milk.
Fluarix Tetra should only be used during breast-feeding when the possible advantages outweigh the potential risks.
Adverse Reactions
Adverse reactions reported for Fluarix Tetra in the different age groups are listed according to the following frequency categories: Very common (≥1/10); Common (≥1/100 to <1/10); Uncommon (≥1/1,000 to <1/100); Rare (≥1/10,000 to <1/1,000); Very rare (<1/10,000).
Clinical trial data: Adults: A clinical study with Fluarix Tetra in adults has evaluated the incidence of adverse reactions in subjects ≥18 years who received one dose of Fluarix Tetra (N = 3,036) or Fluarix (N = 1,010).
The following adverse reactions per dose have been reported: See Table 4.

Click on icon to see table/diagram/image

Children aged 6 months to <18 years: Two clinical studies evaluated the reactogenicity and safety of Fluarix Tetra in children who received at least one dose of Fluarix Tetra or a control vaccine.
One study enrolled children 3 to <18 years of age who received Fluarix Tetra (N = 915) or Fluarix (N = 912). The second study enrolled children 6 to <36 months of age who received Fluarix Tetra (N = 6,006) or a non-influenza vaccine control (N = 6,012) (see Pharmacology: Pharmacodynamics under Actions).
The following adverse reactions per dose have been reported: See Table 5.

Click on icon to see table/diagram/image

Post-marketing data: The following adverse reactions have been observed for Fluarix and/or Fluarix Tetra during post-marketing surveillance.1 (See Table 6.)

Click on icon to see table/diagram/image
Drug Interactions
Fluarix Tetra can be concomitantly administered with pneumococcal vaccines (see Pharmacology: Pharmacodynamics under Actions).
If Fluarix Tetra is to be given at the same time as another injectable vaccine, the vaccines should always be administered at different injection sites.
False positive ELISA serologic tests for HIV-1, Hepatitis C, and especially HTLV-1 may occur following influenza vaccination. These transient false-positive results may be due to cross-reactive IgM elicited by the vaccine. For this reason, a definitive diagnosis of HIV-1, Hepatitis C, or HTLV-1 infection requires a positive result from a virus-specific confirmatory test (e.g. Western Blot or immunoblot).
Caution For Usage
Instructions for Use/Handling: The vaccine presents as a colourless to slightly opalescent suspension.
The syringe should be shaken and inspected visually for any foreign particulate matter and/or variation of physical aspect prior to administration. In the event of either being observed, discard the vaccine.
Instructions for administration of the vaccine presented in a PRTC pre-filled syringe: Holding the syringe barrel in one hand (avoid holding the syringe plunger), unscrew the syringe cap by twisting it anticlockwise.
To attach the needle to the syringe, twist the needle clockwise into the syringe until you feel it lock.
Remove the needle protector, which on occasion can be a little stiff.
Administer the vaccine. Any unused product or waste material should be disposed of in accordance with local requirements.
Storage
Store at 2°C - 8°C (in a refrigerator). Do not freeze. Store in the original package in order to protect from light.
ATC Classification
J07BB02 - influenza, inactivated, split virus or surface antigen ; Belongs to the class of influenza viral vaccines.
Presentation/Packing
Vaccine (inj) (pre-filled syringe) 0.5 mL x 1's, 10's.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in